Current development in nanoformulations of docetaxel

Expert Opinion on Drug Delivery

Volumn 9, Issue 8, 2012, Pages 975-990

  Tan, Qi ^a   Liu, Xiuju ^b   Fu, Xinyu ^c   Li, Qilu ^d   Dou, Jinfeng ^a   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SOUTHWEST MEDICAL UNIVERSITY   (China)

^d Key Laboratory of Cardiovascular Proteomics of Shandong Province   (China)

Author keywords

Docetaxel; Liposome; Micelle; Nanoemulsion; Nanoparticle

Indexed keywords

1,2 DISTEAROYLPHOSPHATIDYLETHANOLAMINE; ALPHA TOCOPHEROL; CERAMIDE; COPOLYMER; DENDRIMER; DOCETAXEL; FIRTECAN; LIPID NANOPARTICLE; LIPOSOME; MACROGOL 10000; MACROGOL 2000; NANOCAPSULE; NANOCARRIER; NANOCRYSTALLINE CELLULOSE; NANOPARTICLE; NANOSTRUCTURE LIPID CARRIER; NK 105; PACLITAXEL; PHOSPHATIDYLETHANOLAMINE; POLOXAMER; POLY(ETHYLENE GLYCOL CYANOACRYLATE CO CHOLESTERYLCYANOACRYLATE); POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIDE; POLYSORBATE 80; QUANTUM DOT; SILICA NANORATTLE; SOLID LIPID NANOPARTICLE; SUCCINIC ACID METHYL ESTER; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE TOXICITY; BIODEGRADABILITY; BREAST CANCER; CANCER CELL; CELL MEMBRANE; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CHRONIC TOXICITY; CONTROLLED DRUG RELEASE; CYTOPLASM; DRUG BINDING; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG QUALITY; DRUG RETENTION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STORAGE; EFFERVESCENT TABLET; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LIPID BILAYER; MICELLE; NANOEMULSION; NANOFORMULATION; NANOPHARMACEUTICS; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; RETICULOENDOTHELIAL SYSTEM; REVIEW; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; MICELLES; NANOPARTICLES; POLYSORBATES; SOLUBILITY; TAXOIDS;

EID: 84864212836     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.696606     Document Type: Review

References (86)

1. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114
2. Snyder JP, Nettles JH, Cornett B, et al. The binding conformation of taxol in beta-tubulin: A model based on electron crystallographic density. Proc Natl Acad Sci USA 2001;98:5312-16
3. Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999;10:947-59
4. Van Poppel H. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. Can J Urol 2005;12:81-5
5. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55
6. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995;13:314-22
7. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995;13:645-51
8. Kaye SB, Piccart M, Aapro M, et al. Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer-an updated overview. Eur J Cancer 1997;33:2167-70
9. Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): A phase II trial. Am J Clin Oncol 2000;23:341-4
10. Friedland D, Cohen J, Miller R Jr, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999;26(5 Suppl 17):19-23
11. Zhang W, Shi Y, Chen Y, et al. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance. Eur J Pharm Biopharm 2010;75:341-53
12. Yanasarn N, Sloat BR, Cui Z. Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel. Int J Pharm 2009;379:174-80
13. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008;26(1):57-64
14. Baker J, Ajani J, Scotte F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009;13:49-59
15. Chaudhari KR, Ukawala M, Manjappa AS, et al. Opsonization, biodistribution, cellular uptake and apoptosis study of PEGylated PBCA nanoparticle as potential drug delivery carrier. Pharm Res 2012;29:53-68
16. Drummond DC, Meyer O, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691-743
17. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995;13:914-20
18. Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: From basics to clinical applications. J Control Release 1998;53:275-9
19. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001;46:169-85
20. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44
21. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-19
22. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009;100:572-9
23. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986;46:6387-92
24. Jia L, Garza M, Wong H, et al. Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice. J Pharm Biomed Anal 2002;28:65-72
25. Kotwani RN, Gokhale PC, Bodhe PV, et al. A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates. Int J Pharm 2002;238:11-15
26. Zhao L, Wei YM, Zhong XD, et al. PK and tissue distribution of docetaxel in rabbits after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal 2009;49:989-96
27. Muthu MS, Kulkarni SA, Xiong J, Feng SS. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm 2011;421:332-40
28. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999;16:1550-6
29. Mu L, Elbayoumi TA, Torchilin VP. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int J Pharm 2005;306:142-9
30. Muthu MS, Kulkarni SA, Raju A, Feng SS. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials 2012;33(12):3494-501
31. Yuan Z, Chen D, Zhang S, Zheng Z. Preparation, characterization and evaluation of docetaxel-loaded, folate-conjugated PEG-liposomes. Yakugaku Zasshi 2010;130:1353-9
32. Li X, Tian X, Zhang J, et al. In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel. Int J Nanomedicine 2011;6:1167-84
33. Zhai G, Wu J, Yu B, et al. A transferrin receptor-targeted liposomal formulation for docetaxel. J Nanosci Nanotechnol 2010;10:5129-36
34. Hwang HY, Kim IS, Kwon IC, Kim YH. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release 2008;128:23-31
35. Saremi S, Atyabi F, Akhlaghi SP, et al. Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: Preparation, in vitro and ex vivo evaluation. Int J Nanomedicine 2011;6:119-28
36. Hruby M, Konak C, Ulbrich K. Polymeric micellar pH-sensitive drug delivery system for doxorubicin. J Control Release 2005;103:137-48
37. Duncan R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Technol Today 1999;2:441-9
38. Ungaro F, Conte C, Ostacolo L, et al. Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: Features, antiproliferative activity and in vivo toxicity. Nanomedicine 2011;xx:1-10
39. Yuk SH, Oh KS, Koo H, et al. Multi-core vesicle nanoparticles based on vesicle fusion for delivery of chemotherapic drugs. Biomaterials 2011;32:7924-31
40. Gan CW, Feng SS. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials 2010;31:7748-57
41. Kulkarni SA, Feng SS. Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier. Nanomedicine (Lond) 2011;6:377-94
42. Koopaei MN, Dinarvand R, Amini M, et al. Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: Preparation, characterization, and cytotoxicity studies. Int J Nanomedicine 2011;6:1903-12
43. Sun B, Feng SS. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine (Lond) 2009;4:431-45
44. Cho HJ, Yoon HY, Koo H, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic for tumor-targeted delivery of docetaxel. Biomaterials 2011;32:7181-90
45. Choi KY, Min KH, Yoon HY, et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 2011;32:1880-9
46. Platt VM, Szoka FC Jr. Anticancer therapeutics: Targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008;5:474-86
47. Zhang P, Chen L, Zhang Z, et al. Pharmacokinetics in rats and efficacy in murine ovarian cancer model for solid lipid nanoparticles loading docetaxel. J Nanosci Nanotechnol 2010;10:7541-4
48. Xu Z, Chen L, Gu W, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009;30:226-32
49. Liu D, Liu Z, Wang L, et al. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 2011;85:262-9
50. Gao Y, Yang R, Zhang Z, et al. Solid lipid nanoparticles reduce systemic toxicity of docetaxel: Performance and mechanism in animal. Nanotoxicology 2011;5:636-49
51. Xu Z, Chen L, Gu W, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 2009;30:226-32
52. Liu D, Liu F, Liu Z, et al. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm 2011;8:2291-301
53. Zhao X, Zhao Y, Geng L, et al. Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: Evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:3721-7
54. Wu M, Gunning W, Ratnam M. Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev 1999;8:775-82
55. Gaucher G, Dufresne MH, Sant VP, et al. Block copolymer micelles: Preparation, characterization and application in drug delivery. J Control Release 2005;109:169-88
56. Muthu MS, Avinash Kulkarni S, Liu Y, Feng SS. Development of docetaxel-loaded vitamin E TPGS micelles: Formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine (Lond) 2012;7(3):353-64
57. Liu Z, Liu D, Wang L, et al. Docetaxel-loaded pluronic p123 polymeric micelles: In vitro and in vivo evaluation. Int J Mol Sci 2011;12:1684-96
58. Mu CF, Balakrishnan P, Cui FD, et al. The effects of mixed MPEG-PLA/pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 2010;31:2371-9
59. Ostacolo L, Marra M, Ungaro F, et al. In vitro anticancer activity of docetaxel-loaded micelles based on poly (ethylene oxide)- poly(epsiloncaprolactone) block copolymers: Do nanocarrier properties have a role? J Control Release 2010;148:255-63
60. Mikhail AS, Allen C. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: Synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromolecules 2010;1011:1273-80
61. Xie Z, Lu T, Chen X, et al. Synthesis, self-assembly in water, and cytotoxicity of MPEG-block-PLLA/DX conjugates. J Biomed Mater Res A 2009;88:238-45
62. Zhang Y, Wang X, Wang J, et al. Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells. Pharm Res 2011;28:1167-78
63. Mi Y, Liu Y, Feng SS. Formulation of Docetaxel by folic acid-conjugated d-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials 2011;32:4058-66
64. Reisen JV, Polley GT, Verheijen PJ. Structural targeting for heat integration retrofit. Appl Therm Eng 1998;18:283-94
65. Chilkoti A, Dreher MR, Meyer DE, Raucher D. Targeted drug delivery by thermally responsive polymers. Adv Drug Deliv Rev 2002;54:613-30
66. Riehemann K, Schmitt O, Ehlers EM. The effects of thermochemotherapy using cyclophosphamide plus hyperthermia on the malignant pleural mesothelioma in vivo. Ann Anat 2005;187:215-23
67. Liu B, Yang M, Li R, et al. The antitumor effect of novel docetaxel-loaded thermosensitive micelles. Eur J Pharm Biopharm 2008;69:527-34
68. Na K. pH-sensitive polymeric micelles for the effective delivery of anti-cancer drug. Korean J Gastroenterol 2007;49:314-19
69. Chen DW, Yan L, Qiao MX, et al. Preparation of docetaxel-loaded pH-sensitive block copolymer micelles. Yao Xue Xue Bao 2008;43:1066-70
70. Gajbhiye V, Kumar PV, Tekade RK, Jain NK. Pharmaceutical and biomedical potential of PEGylated dendrimers. Curr Pharm Des 2007;13:415-29
71. Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine 2005;1(1):22-30
72. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: Current status and future prospects. FASEB J 2005;19:311-30
73. Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007;59:454-77
74. Gajbhiye V, Jain NK. The treatment of glioblastoma xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 2011;32:6213-25
75. Li X, Du L, Wang C, et al. Highly efficient and lowly toxic docetaxel nanoemulsions for intravenous injection to animals. Pharmazie 2011;66:479-83
76. Venkateshwarlu I, Prabhakar K, Ali M, Kishan V. Development and in vitro cytotoxic evaluation of parenteral docetaxel lipid nanoemulsions for application in cancer treatment. PDA J Pharm Sci Technol 2010;64:233-41
77. Zhao M, Su M, Lin X, et al. Evaluation of docetaxel-loaded intravenous lipid emulsion: Pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity. Pharm Res 2010;27:1687-702
78. Kranz H, Jurgens K, Pinier M, Siepmann J. Drug release from MCC- and carrageenan-based pellets: Experiment and theory. Eur J Pharm Biopharm 2009;73:302-9
79. Khan GM, Zhu JB. Studies on drug release kinetics from ibuprofen-carbomer hydrophilic matrix tablets: Influence of co-excipients on release rate of the drug. J Control Release 1999;57:197-203
80. Javadzadeh Y, Shariati H, Movahhed-Danesh E, Nokhodchi A. Effect of some commercial grades of microcrystalline cellulose on flowability, compressibility, and dissolution profile of piroxicam liquisolid compacts. Drug Dev Ind Pharm 2009;35:243-51
81. Klemm D, Kramer F, Moritz S, et al. Nanocelluloses: A new family of nature-based materials. Angew Chem Int Ed Engl 2011;50:5438-66
82. Habibi Y, Lucia LA, Rojas OJ. Cellulose nanocrystals: Chemistry, self-assembly, and applications. Chem Rev 2010;110:3479-500
83. Jackson JK, Letchford K, Wasserman BZ, et al. The use of nanocrystalline cellulose for the binding and controlled release of drugs. Int J Nanomedicine 2011;6:321-30
84. Nassar T, Attili-Qadri S, Harush-Frenkel O, et al. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation. Cancer Res 2011;71(8):3018-28
85. Chen D, Li LL, Tang FQ, Qi S. Facile and scalable synthesis of tailored silica ''Nanorattle'' structures. Adv Mater 2009;21:3804-7
86. Li L, Tang F, Liu H, et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano 2010;4(11):6874-82